文档介绍：Choosing First-Line Therapy in Chronic Hepatitis B
This program is supported by an unrestricted educational grant from
About These Slides
Users are encouraged to include these slides in their own presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent.
These slides may not be published or posted online or used for any mercial purpose without written permission from Clinical Care Options.
We are grateful to Emmet B. Keeffe, MD, MACP, with the Stanford University Medical Center in Palo Alto, California, for aiding in the content development of these slides.
Participants have an implied responsibility to use the newly acquired information to enhance patient es and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, parison with mendations of other authorities.
Outline
Introduction: Considerations for Selecting Initial HBV Therapy
Case te: First-line Treatment in an HBeAg-Positive Patient
Review of key factors in determining initial therapy in HBeAg-positive patients
Case te: First-line Treatment in an HBeAg-Negative Patient
Review of key factors in determining initial therapy in HBeAg-negative patients
Case te: First-line Treatment in a Cirrhotic Patient With Hepatitis B
Review of key factors in determining initial therapy in cirrhotics
Considerations for Selecting First-Line Therapy in Hepatitis B
Goals of therapy
Candidacy for therapy
Baseline patient factors
HBeAg positive vs HBeAg negative
HBV genotype
HBV DNA level
ALT level
Presence or absence of cirrhosis
Significant orbidities (ie, depression, kidney disease)
Treatme